ReviewCurrent microbiology2022
Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review.
Review in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Antibacterial efficacy of Nonea lutea-mediated silver and gold nanoparticles against multidrug-resistant clinical pathogens harboring virulence and resistance genes.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Rapid Antimicrobial Susceptibility Testing Using Direct Centrifugation Significantly Reduces Turnaround Time While Maintaining High Diagnostic Accuracy in Bloodstream Infections.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Effective Abatement of Multidrug-resistant Pathogens Employing Natural Polyphenols and Polyphenol-based Formulations: A Systematic Review and Integrated Network Pharmacology Approach.Applied biochemistry and biotechnology · 2026Review
- Piezoelectric Nanocoatings on Bio-Interfaces: Microenvironment Remodeling, Biofilm Disruption, and Immunomodulatory Integration.Microorganisms · 2026Review
- Comparative genomic analysis of clinical Pseudomonas aeruginosa isolates from Iraq: insights into genome diversity, antimicrobial resistance, and phylogenetic relatedness.Molecular biology reports · 2026Article
- Genomic and structural analysis of dacB variants associated with cephalosporin resistance in Pseudomonas aeruginosa.Scientific reports · 2026Article
- Isolation and characterization of two phages infectingThe Journal of general virology · 2026Article
- Sustainable synthesis of mono-, bi- and tri-metallic nanoparticles using endophytic fungi: characterization and different applications.RSC advances · 2026Review
- Nanotechnology revolutionizing antimicrobial therapy for superbug infections.Discover nano · 2026Review
- Lactic Acid Bacteria-derived Bacteriocins: A Promising Antimicrobial Strategy against Multidrug-resistant for Neonatal Sepsis Pathogens.Probiotics and antimicrobial proteins · 2026Review
- Nanoparticle-Based Strategies to Combat Multidrug-Resistant Bacteria: Mechanisms, Applications, and Future Perspectives.MicrobiologyOpen · 2026Review
- Nanodiamonds Co-Localize withPharmaceutics · 2026Article
- High-copy plasmid engineering enhances recombinant protein and antimicrobial peptide production in Corynebacterium glutamicum.Microbial cell factories · 2026Article
- Molecular characterization and immunoinformatics-based design of a multi-epitope vaccine against Staphylococcus nepalensis.Antonie van Leeuwenhoek · 2026Article
- Molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli among children and farm animals in Agogo, Ghana.BMC microbiology · 2026Article
- Effect ofJournal of veterinary research · 2026Article
- Uncovering the bactericidal potential of extract and multi-targeting phytochemicals from Mirabilis longiflora L. leaves against multidrug-resistant Pseudomonas aeruginosa and Bacillus cereus.Scientific reports · 2026Article
- Genomic insights and emerging therapeutics in community-associated MRSA.Annals of medicine and surgery (2012) · 2026Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are several bacteria called superbugs that are resistant to multiple antibiotics which can be life threatening specially for critically ill and hospitalized patients. This article provides up-to-date treatment strategies employed against some major superbugs, like methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus, multidrug-resistant Pseudomonas aeruginosa, and multidrug-resistant Escherichia coli. The pathogen-directed therapeutics decrease the toxicity of bacteria by altering their virulence factors by specific processes. On the other hand, the host-directed therapeutics limits these superbugs by modulating immune cells, enhancing host cell functions, and modifying disease pathology. Several new antibiotics against the global priority superbugs are coming to the market or are in the clinical development phase. Medicinal plants possessing potent secondary metabolites can play a key role in the treatment against these superbugs. Nanotechnology has also emerged as a promising option for combatting them. There is urgent need to continuously figure out the best possible treatment strategy against these superbugs as resistance can also be developed against the new and upcoming antibiotics in future. Rational use of antibiotics and maintenance of proper hygiene must be practiced among patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.